Vanguard Group Inc. lifted its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 8.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,459,679 shares of the medical research company’s stock after purchasing an additional 700,051 shares during the quarter. Vanguard Group Inc. owned 7.94% of Exact Sciences Corporation worth $334,589,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Exact Sciences Corporation by 1.2% during the 2nd quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock valued at $243,518,000 after purchasing an additional 80,589 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Exact Sciences Corporation by 1,534.3% during the 1st quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock valued at $59,061,000 after purchasing an additional 2,347,476 shares during the period. Eagle Asset Management Inc. raised its stake in shares of Exact Sciences Corporation by 19.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,857,185 shares of the medical research company’s stock valued at $65,688,000 after purchasing an additional 304,598 shares during the period. FMR LLC raised its stake in shares of Exact Sciences Corporation by 0.8% during the 1st quarter. FMR LLC now owns 1,746,473 shares of the medical research company’s stock valued at $41,252,000 after purchasing an additional 13,420 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Exact Sciences Corporation by 6.4% during the 2nd quarter. Northern Trust Corp now owns 1,451,829 shares of the medical research company’s stock valued at $51,351,000 after purchasing an additional 86,747 shares during the period. Institutional investors own 85.22% of the company’s stock.

A number of research firms recently issued reports on EXAS. Robert W. Baird reiterated a “buy” rating and set a $49.00 price objective on shares of Exact Sciences Corporation in a research note on Friday. Zacks Investment Research cut Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Vetr cut Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $37.46 target price for the company. in a research report on Wednesday, June 28th. Leerink Swann restated an “outperform” rating and set a $50.00 target price (up from $45.00) on shares of Exact Sciences Corporation in a research report on Thursday, September 21st. Finally, Lake Street Capital boosted their target price on Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $43.71.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $39.41, for a total value of $230,390.86. Following the sale, the chief financial officer now directly owns 19,861 shares of the company’s stock, valued at $782,722.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the completion of the sale, the senior vice president now directly owns 64,991 shares in the company, valued at $3,064,975.56. The disclosure for this sale can be found here. Insiders sold 237,444 shares of company stock worth $10,412,421 over the last ninety days. Insiders own 4.00% of the company’s stock.

Exact Sciences Corporation (NASDAQ EXAS) opened at 48.63 on Monday. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $50.65. The stock has a 50 day moving average price of $43.40 and a 200-day moving average price of $35.15. The stock’s market capitalization is $5.79 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The firm had revenue of $57.65 million for the quarter, compared to analysts’ expectations of $47.73 million. On average, equities analysts anticipate that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Has $334.59 Million Position in Exact Sciences Corporation (EXAS)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/09/vanguard-group-inc-has-334-59-million-position-in-exact-sciences-corporation-exas.html.

Exact Sciences Corporation Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.